Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
NewAmsterdam Pharma Company ( (NAMS) ) just unveiled an update.
NewAmsterdam Pharma Company has entered into an underwriting agreement for a public offering of its ordinary shares and pre-funded warrants, raising approximately $452.6 million. The underwriters have exercised their option to purchase additional shares, with the offering expected to enhance the company’s financial position as it pursues its clinical trials and commercialization efforts for its LDL-lowering therapies.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients with cardiovascular disease and elevated LDL cholesterol. The company aims to address unmet needs for safe and effective LDL-lowering therapies, particularly for patients who do not tolerate existing treatments well.
YTD Price Performance: 124.62%
Average Trading Volume: 654,633
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.32B
For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.
